Evidence map›Paper›PMID 36296574›Full record

ArticleMolecules (Basel, Switzerland)2022

Nipecotic Acid Derivatives as Potent Agents against Neurodegeneration: A Preliminary Study.

Georgios Papagiouvannis, Panagiotis Theodosis-Nobelos, Eleni A Rekka

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Georgios PapagiouvannisDepartment of Pharmacy, School of Health Sciences, Frederick University, 1036 Nicosia, Cyprus.
Panagiotis Theodosis-NobelosDepartment of Pharmacy, School of Health Sciences, Frederick University, 1036 Nicosia, Cyprus.
Eleni A RekkaDepartment of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Frederick University · CYAristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a common neurodegenerative disorder characterized by memory loss and cognitive impairment. Its pathology has not been fully clarified and therefore highly effective treatments have not been obtained yet. Almost all the current treatment options aim to alleviate only the symptoms and not to eliminate the disease itself. Acetylcholinesterase inhibitors are the main therapeutic agents against AD, whereas oxidative stress and inflammation have been found to be of great significance for the development and progression of neurodegeneration. In this work, ethyl nipecotate (ethyl-piperidine-3-carboxylate), a heterocyclic carboxylic acid derivative, which acts as a GABA reuptake inhibitor and has been used in research for diseases involving GABAergic neurotransmission dysfunction, was amidated with various carboxylic acids bearing antioxidant and/or anti-inflammatory properties (e.g., ferulic acid, sinapic acid, butylated hydroxycinnamic acid). Most of our compounds have significant antioxidant potency as lipid peroxidation inhibitors (IC

Indexed as

Alzheimer DiseaseCoumaric AcidsAcetylcholinesteraseAnimalsAnti-Inflammatory AgentsAntioxidantsCarrageenanCholinesterase InhibitorsGABA Uptake InhibitorsNipecotic AcidsPiperidinesRatsReducing AgentsAcetylcholinesteraseAnti-Inflammatory AgentsAntioxidantsCarrageenanCholinesterase InhibitorsCoumaric AcidsGABA Uptake InhibitorsNipecotic AcidsPiperidinesReducing Agentsacetylcholinesterase inhibitorsAlzheimer’s Diseaseinflammationmulti-targeting compoundsnipecotic acidoxidative stress

Identifiers

PMID36296574
PMCPMC9609801
OpenAlexW4306762131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.